Lipopolysaccharide Products for Vaccine Development
Bacterial lipopolysaccharides (LPS) have been recognized as the active component of gram negative bacterial endotoxins. The low-toxicity derivative Monophosphoryl lipid A (MPLA) is a TLR4 agonist and can induces a strong Th1 response. It has been used extensively in clinical trials as a component in prophylactic and therapeutic vaccines targeting infectious disease, cancer and allergies. Creative Biolabs are confident in offering the best products upon request. We can provide various formulations of adjuvants derived from bacterial cell wall for testing adjuvantcy with a given antigen or use in preclinical vaccine development. Creative Biolabs provides you the best goods with competitive price.
| CAT | Product Name | Product Overview | Type | Datasheet | Size | Price |
|---|---|---|---|---|---|---|
| VAdv-Ly0011 | Monophosphoryl Lipid A (S. enterica Minnesota, 595) | Monophosphoryl Lipid A, derivative from S. enterica Minnesota, 595, a TLR4-based vaccine adjuvant. | Lipopolysaccharide |  |
1 mg |
$1781.00 |
| VAdv-Ly0012 | Monophosphoryl Lipid A (Synthetic) | Synthetic Monophosphoryl Lipid A, pure compound, a TLR4-based vaccine adjuvant. | Lipopolysaccharide | |
1 mg |
$1463.00 |
| VAdv-Ly0030 | Lipopolysaccharide (E. coli 0111:B4 strain) | Lipopolysaccharide from E. coli 0111:B4 strain, a TLR4-based adjuvant. | Lipopolysaccharide | |
5 x 10e6 EU |
$1779.00 |
| VAdv-Ly0031 | Synthetic Monophosphoryl Lipid A | Synthetic monophosphoryl lipid A, a TLR4 agonist vaccine adjuvant. | Lipopolysaccharide | |
1 mg |
$1779.00 |
| VAdv-Ly0054 | Lipopolysaccharides (Salmonella typhimurium) | Lipopolysaccharide from Salmonella typhimurium, a TLR4-based adjuvant. | Lipopolysaccharide | |
1 mg |
$958.00 |
| VAdv-Ly0082 | LPS (E. coli O55:B5 strain) | Lipopolysaccharide from E. coli O55:B5 strain, a TLR4-based adjuvant. | Lipopolysaccharide | |
1 mg |
$1072.00 |
| VAdv-Wyb0083 | Synthetic Monophosphoryl Lipid A (>99% Purity) | Synthetic monophosphoryl lipid A (>99% Purity), a TLR4 agonist vaccine adjuvant. | Lipopolysaccharide | |
1 mg |
$1072.00 |
| VAdv-Wyb0084 | Synthetic Monophosphoryl 3-Deacyl Lipid A (>99% Purity) | Synthetic monophosphoryl 3-Deacyl lipid A, MPLA structural analog, a TLR4 agonist vaccine adjuvant | Lipopolysaccharide | |
1 mg |
$1072.00 |
| VAdv-Wyb0085 | Synthetic Monophosphoryl Hexa-acyl Lipid A, 3-Deacyl (>99% Purity) | Synthetic monophosphoryl hexa-acyl lipid A, 3-Deacyl, MPLA structural analog, a TLR4 agonist vaccine adjuvant | Lipopolysaccharide | |
1 mg |
$1072.00 |
| VAdv-Lsx0002 | Monophosphoryl Lipid A-504 | Synthetic monophosphoryl lipid A 504, a structural analog of detoxified MPLA derived from E. coli lipopolysaccharide, only the length of a single fatty acid chain is different. | Lipopolysaccharide | |
1 mg |
$993.00 |
| VAdv-Lsx0003 | 3A-MPLA | Monophosphoryl Tri-acyl Lipid A | Lipopolysaccharide | |
1 mg |
$5640.00 |
| VAdv-Lsx0004 | 4A-MPLA | Monophosphoryl Tetra-acyl Lipid A | Lipopolysaccharide | |
1 mg |
$1770.00 |
| VAdv-Lsx0005 | D-(+)-trehalose 6,6'-dibehenate | Incorporation of the glycolipid trehalose 6,6'-dibehenate (TDB) into cationic liposomes composed of the quaternary ammonium compound dimethyldioctadecylammonium (DDA) | Lipopolysaccharide | |
5 mg |
$937.00 |
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
